683 Capital Management LLC Purchases New Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

683 Capital Management LLC acquired a new stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 163,109 shares of the company's stock, valued at approximately $522,000. 683 Capital Management LLC owned approximately 0.33% of Checkpoint Therapeutics as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of CKPT. Schonfeld Strategic Advisors LLC bought a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $150,000. Northern Trust Corp lifted its stake in Checkpoint Therapeutics by 16.4% in the fourth quarter. Northern Trust Corp now owns 72,563 shares of the company's stock valued at $232,000 after buying an additional 10,232 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Checkpoint Therapeutics during the fourth quarter valued at $35,000. Stifel Financial Corp bought a new position in shares of Checkpoint Therapeutics during the fourth quarter worth about $32,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after acquiring an additional 6,486 shares during the period. Institutional investors own 22.00% of the company's stock.

Insiders Place Their Bets

In related news, CFO William Garrett Gray sold 12,322 shares of Checkpoint Therapeutics stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total value of $49,904.10. Following the transaction, the chief financial officer now owns 1,446,322 shares of the company's stock, valued at approximately $5,857,604.10. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO James F. Oliviero III sold 15,090 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $4.04, for a total transaction of $60,963.60. Following the sale, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at $15,190,113.16. This represents a 0.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,976 shares of company stock worth $174,895. 2.10% of the stock is owned by insiders.

Checkpoint Therapeutics Stock Performance

Shares of Checkpoint Therapeutics stock remained flat at $4.15 during trading on Thursday. The stock had a trading volume of 456,887 shares, compared to its average volume of 2,151,911. The firm's fifty day simple moving average is $3.89 and its two-hundred day simple moving average is $3.59. Checkpoint Therapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $4.50. The stock has a market capitalization of $347.62 million, a price-to-earnings ratio of -2.26 and a beta of 1.18.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. On average, analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. D. Boral Capital reaffirmed a "buy" rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a report on Monday, March 31st. Lake Street Capital reissued a "hold" rating and issued a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.